Latest News

Rising employer premiums averaging 9.5% erode wages, forcing workers to delay care.

ADAPs achieve 87% viral suppression but face funding crisis as multiple policies erode 340B rebates.

Break Up Big Medicine Act would force structural separation of insurers, PBMs, and pharmacies.

Medicare drug negotiation's third wave includes Biktarvy, raising HIV treatment access concerns.

FY2026 preserves HIV funding but level funding can't support long-acting therapeutics or growing needs.

340B program drifted from patient benefit; federal reform needed for transparency and accountability.

Enhanced ACA subsidies expired Jan 1; Senate framework proposes two-year extension with restrictions.

2025 healthcare crises result from policy choices as ACA subsidies expire, HIV care deteriorates, and state pricing experiments proliferate.

World AIDS Day honors resilience of HIV advocates and communities resisting policy failures and system barriers to care.

Senate HELP Committee hearing reveals how 340B drug program expansion reflects hospital business strategy rather than patient benefit.

European price controls demonstrate MFN policy risks: delayed access, treatment rationing, and pharmaceutical innovation collapse.

September government shutdown threatens healthcare systems during November open enrollment, risking coverage loss for 22 million Americans.

Congressional Budget Office confirms 340B program expansion driven by hospital exploitation rather than pharmaceutical price inflation.

Trump administration's revocation of competition executive order accelerates healthcare consolidation and threatens patient access.

Most Favored Nation pricing threatens to import restrictive QALY-based frameworks that discriminate against expensive treatments.

HRSA clarifies 340B eligibility for STI clinics while manufacturers challenge Ryan White program participation.

HRSA's 340B pilot program replicates existing successful models rather than addressing structural program exploitation.

Proposed PEPFAR defunding would eliminate the world's most successful global HIV program and damage international health capacity.

Expiration of enhanced ACA subsidies threatens to increase premiums 75% and reduce marketplace enrollment by millions.

340B program expansion drains billions from state Medicaid budgets while failing to deliver promised drug cost savings.